43 Thorndike Street
Cambridge, MA 02141
United States
617 682 0917
https://amylyx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 384
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Joshua B. Cohen | Co-Founder, Co-CEO & Director | 1M | N/A | 1992 |
Mr. Justin B. Klee | Co-Founder, Co-CEO & Director | 1M | N/A | 1991 |
Mr. James M. Frates M.B.A. | Chief Financial Officer | 695.12k | N/A | 1967 |
Ms. Gina M. Mazzariello | Chief Legal Officer & General Counsel | 794.83k | N/A | 1971 |
Mr. Tom Holmes | Chief Technical Operations Officer | N/A | N/A | N/A |
Lindsey Allen | Head of Investor Relations & Communications | N/A | N/A | N/A |
Ms. Shauna Horvath | Head of Global Marketing | N/A | N/A | N/A |
Ms. Linda A. Arsenault | Chief Human Resources Officer | N/A | N/A | N/A |
Mr. Chris Aiello | Head of Canada & GM | N/A | N/A | N/A |
Mr. Keith White | Head of Global Market Access | N/A | N/A | N/A |
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 March 2024 is 8. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 8; Compensation: 9.